Compare iShares Russell 2000 ETF (IWM) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Russell 2000 ETF vs Mesoblast Limited — how do they compare? iShares Russell 2000 ETF trades at $279.42 (market cap $77.70B), while Mesoblast Limited trades at $14.24 (market cap $1.75B). The key difference: iShares Russell 2000 ETF is far larger — about 44.4× Mesoblast Limited's market cap, and iShares Russell 2000 ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Russell 2000 ETF for 83 Days and Mesoblast Limited for 15 Days on average.
| IWM | MESO | |
|---|---|---|
Market Cap | $77.70B | $1.75B |
Volume | 35,598,983 | 239,027 |
52-Week High | $305.06 | $20.96 |
52-Week Low | $229.13 | $13.19 |
Typical Hold Time | 83 Days | 15 Days |
Sector | — | Health |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IWM, the iShares Russell 2000 ETF tracking US small-cap stocks, trades at $279.1, up 0.5% on the day. Technical indicators are predominantly bearish, with moving averages and ADX signaling a downtrend, though oscillators like RSI are neutral. The fund lacks traditional valuation ratios as it is an ETF, and recent news highlights its underperformance versus the S&P 500 over the past decade, with concerns about its inclusion of unprofitable companies.
The outlook for IWM is clouded by persistent underperformance and sensitivity to interest rate hikes, which pressure small caps. While offering diversification away from large-cap tech, the fund faces headwinds from economic tightening and narrow market breadth. A rebound hinges on broader market participation and favorable macroeconomic conditions, but near-term risks remain elevated.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
